Summary
A pivotal open-label trial of rVIII-SingleChain in adolescents and adults with hemophilia A was conducted. Pharmacokinetic results indicate that, when compared with octocog alfa, this agent has lower clearance, a greater area under the curve, and a longer half-life. rVIII-SingleChain is efficacious and well tolerated when it is used prophylactically or on demand.
- AFFINITY trial
- NCT01486927
- rVIII-SingleChain
- hemophilia A
- hemophilia prophylaxis
- clinical trial
- hemophilia treatment
- pharmacokinetics
- thrombotic disorders
- hematology clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.